person · Reporting owner

SIDRANSKY DAVID

Disclosed activity across 7 companies

Tapewire entity: 56595
SEC CIK: 0001277161

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ASCENTAGE PHARMA GROUP INTERNATIONALAAPG · Entity 4672	Director	March 18, 2026	March 23, 2026
Ayala Pharmaceuticals, Inc.ADXS · Entity 93434	Director	January 19, 2023	January 23, 2023
CHAMPIONS ONCOLOGY, INC.CSBR · Entity 7013	Director	November 05, 2025	November 07, 2025
Cactus Acquisition Corp. 1 LtdCCTSU · Entity 88589	Director	October 28, 2021	November 04, 2021
Galmed Pharmaceuticals Ltd.GLMD · Entity 8348	Director	March 18, 2026	March 18, 2026
Orgenesis Inc.ORGS · Entity 81814	Director	December 20, 2023	December 21, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ASCENTAGE PHARMA GROUP INTERNATIONAL

Report date March 18, 2026 · Filed March 23, 2026 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	10,641	Reported balance Holding disclosure · report date 2026-03-18 · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · Balance 10,641 F1: The number of Ordinary Shares were inadvertently not reported in the original submission.
OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.14 · Expires 2035-11-26	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 2 Amendment: may correct only part of an earlier disclosure. 1 source row Row 2 · Balance Not disclosed F3: The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant. F2: The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025. F5: The number of Share Options and/or vesting were inadvertently incorrectly reported in the original submission.
Restricted share unitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 3 Amendment: may correct only part of an earlier disclosure. 1 source row Row 3 · Balance Not disclosed F4: Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. F5: The number of Share Options and/or vesting were inadvertently incorrectly reported in the original submission.

Filing footnotes · ownership attribution and instrument terms

F1: The number of Ordinary Shares were inadvertently not reported in the original submission.

F2: The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025.

F3: The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.

F4: Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.

F5: The number of Share Options and/or vesting were inadvertently incorrectly reported in the original submission.

Ayala Pharmaceuticals, Inc.

Report date January 19, 2023 · Filed January 23, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHeld by Reporting Person's Son	46	Reported balance After 2023-01-19 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2023-01-19 · Grant · Acquired 46 · Balance 46 F1: Received in exchange for 250 shares of the common stock of Ayala Pharmaceuticals, Inc. ("Old Ayala") in the merger of Old Ayala into the Issuer (the "Merger"). On the day prior to the effective date of the Merger, the closing price of Old Ayala's common stock was $0.53 per share, and the closing price of the Issuer's common stock was $2.95 per share.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $55.23 · Expires 2031-06-09	Direct	2,342	Reported balance After 2023-01-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-01-19 · Grant · Acquired 2,342 · Balance 2,342 F3: Received in the Merger in exchange for an employee stock option to acquire 12,500 shares of the common stock of Old Ayala for $10.35 per share. F2: This option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.70 · Expires 2032-06-12	Direct	2,342	Reported balance After 2023-01-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-01-19 · Grant · Acquired 2,342 · Balance 2,342 F5: Received in the Merger in exchange for an employee stock option to acquire 12,500 shares of the common stock of Old Ayala for $1.63 per share. F4: This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $16,128.00 · Expires 2025-05-27	Direct	17	Reported balance Holding disclosure · report date 2023-01-19 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 17 F2: This option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $15,372.00 · Expires 2025-11-04	Direct	42	Reported balance Holding disclosure · report date 2023-01-19 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance 42 F2: This option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $9,252.00 · Expires 2026-11-03	Direct	25	Reported balance Holding disclosure · report date 2023-01-19 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance 25 F2: This option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3,828.00 · Expires 2027-11-01	Direct	25	Reported balance Holding disclosure · report date 2023-01-19 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance 25 F2: This option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $648.00 · Expires 2028-11-04	Direct	25	Reported balance Holding disclosure · report date 2023-01-19 · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · Balance 25 F2: This option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $24.80 · Expires 2029-10-23	Direct	125	Reported balance Holding disclosure · report date 2023-01-19 · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · Balance 125 F2: This option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $52.80 · Expires 2030-05-03	Direct	163	Reported balance Holding disclosure · report date 2023-01-19 · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · Balance 163 F6: Two-thirds of this award is currently vested and the remaining one-third will be vested on May 4, 2023.
Common StockSEC Table I · non-derivative	Direct	93	Reported balance Holding disclosure · report date 2023-01-19 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 93

Filing footnotes · ownership attribution and instrument terms

F1: Received in exchange for 250 shares of the common stock of Ayala Pharmaceuticals, Inc. ("Old Ayala") in the merger of Old Ayala into the Issuer (the "Merger"). On the day prior to the effective date of the Merger, the closing price of Old Ayala's common stock was $0.53 per share, and the closing price of the Issuer's common stock was $2.95 per share.

F2: This option is fully vested and exercisable.

F3: Received in the Merger in exchange for an employee stock option to acquire 12,500 shares of the common stock of Old Ayala for $10.35 per share.

F4: This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.

F5: Received in the Merger in exchange for an employee stock option to acquire 12,500 shares of the common stock of Old Ayala for $1.63 per share.

F6: Two-thirds of this award is currently vested and the remaining one-third will be vested on May 4, 2023.

CHAMPIONS ONCOLOGY, INC.

Report date November 05, 2025 · Filed November 07, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $6.80 · Expires 2035-11-05	Direct	21,216	Reported balance After 2025-11-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-11-05 · Grant · Acquired 21,216 · Balance 21,216 F1: The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 5, 2025, February 5, 2026, May 5, 2026 and August 5, 2026, respectively.

Filing footnotes · ownership attribution and instrument terms

F1: The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 5, 2025, February 5, 2026, May 5, 2026 and August 5, 2026, respectively.

Cactus Acquisition Corp. 1 Ltd

Report date October 28, 2021 · Filed November 04, 2021

This filing explicitly reported no securities owned.

Galmed Pharmaceuticals Ltd.

Report date March 18, 2026 · Filed March 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	11,083	Reported balance Holding disclosure · report date 2026-03-18 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 11,083
Restricted Share UnitsSEC Table I · non-derivative	Direct	1,042	Reported balance Holding disclosure · report date 2026-03-18 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,042 F1: These restricted share units vest on August 7, 2026, subject to the Reporting Person's continued service.
Restricted Share UnitsSEC Table I · non-derivative	Direct	11,666	Reported balance Holding disclosure · report date 2026-03-18 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 11,666 F2: These restricted share units vest in four equal installments on each of May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, subject to the Reporting Person's continued service.
Restricted Share UnitsSEC Table I · non-derivative	Direct	12,500	Reported balance Holding disclosure · report date 2026-03-18 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 12,500 F3: These restricted share units vest in accordance with the following vesting schedule: 1/3 shall vest on August 26, 2026 and the remaining portion shall vest in four equal installments on each of February 26, 2027, August 26, 2027, February 26, 2028 and August 26, 2028, subject to the Reporting Person's continued service.
Options to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $558.00 · Expires 2031-07-15	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed
Options to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $2,080.80 · Expires 2028-07-10	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed

Filing footnotes · ownership attribution and instrument terms

F1: These restricted share units vest on August 7, 2026, subject to the Reporting Person's continued service.

F2: These restricted share units vest in four equal installments on each of May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, subject to the Reporting Person's continued service.

F3: These restricted share units vest in accordance with the following vesting schedule: 1/3 shall vest on August 26, 2026 and the remaining portion shall vest in four equal installments on each of February 26, 2027, August 26, 2027, February 26, 2028 and August 26, 2028, subject to the Reporting Person's continued service.

Orgenesis Inc.

Report date December 20, 2023 · Filed December 21, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.45 · Expires 2033-12-19	Direct	20,450	Reported balance After 2023-12-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-12-20 · Grant · Acquired 20,450 · Balance 20,450 F1: These options were awarded under the Issuer's 2017 Equity Incentive Plan to purchase shares of common stock of the Issuer and vest in one year from the date of the grant, beginning on December 20, 2023, subject to the non-employee director's continued service on the Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: These options were awarded under the Issuer's 2017 Equity Incentive Plan to purchase shares of common stock of the Issuer and vest in one year from the date of the grant, beginning on December 20, 2023, subject to the non-employee director's continued service on the Board of Directors.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Old Ayala, Inc

Report date January 19, 2023 · Filed January 24, 2023

Section 16 reporting ended · disclosed 2023-01-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHeld by Reporting Person's son	Reported balance After 2023-01-19 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2023-01-19 · Disposition to issuer · Disposed 250 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock"), was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.35 · Expires 2031-06-09	Direct	Reported balance After 2023-01-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-01-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock"), was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F3: This option is fully vested and exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.63 · Expires 2032-06-12	Direct	Reported balance After 2023-01-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-01-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock"), was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F4: This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock"), was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock").

F2: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option.

F3: This option is fully vested and exercisable.

F4: This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 12, 2018 Filed Jun 13, 2018 18:36 UTC	Ayala Pharmaceuticals, Inc. ADXS · Entity 93434	GrantCommon stock	3,198	$1.85	$5,916.30	Disclosure SEC source: 0001493152-18-008630 · form4.xml · nonDerivative · entry 1 SIDRANSKY DAVID · CIK 0001277161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,553 F1 · shares: Represents a voluntary at market stock purchase by the reporting person on the open market. Read SEC document
November 02, 2017 Filed Nov 6, 2017 18:00 UTC	Ayala Pharmaceuticals, Inc. ADXS · Entity 93434	GrantOption · Derivative	30,000	$0.00 Strike: $3.19	$0.00	Disclosure SEC source: 0001493152-17-012497 · form4.xml · derivative · entry 1 SIDRANSKY DAVID · CIK 0001277161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-11-02 F1 · shares: This award relates to the annual long term incentive grant awarded by the Compensation Committee following the completion of our 2017 Fiscal Year and is subject to the terms of our 2015 Incentive Plan. The award fully vests on November 2, 2018. Read SEC document
December 09, 2016 Filed Mar 5, 2019 23:47 UTC	Orgenesis Inc. ORGS · Entity 81814	GrantStock Option · Derivative	41,667	$0.00 Strike: $4.80	$0.00	Disclosure SEC source: 0001062993-19-001146 · form4.xml · derivative · entry 1 SIDRANSKY DAVID · CIK 0001277161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,667 Underlying: Common Stock · 41,667 shares Expires 2026-12-09 F1 · shares: Represents post-reverse stock split share amounts. F2 · derivative.exercise_date: These non-plan options were awarded to purchase shares of common stock of the Issuer and vested in equal quarterly installments over a two-year period from the award date. F1 · derivative.underlying_shares: Represents post-reverse stock split share amounts. F1 · balance_after: Represents post-reverse stock split share amounts. Read SEC document
November 03, 2016 Filed Nov 7, 2016 16:32 UTC	Ayala Pharmaceuticals, Inc. ADXS · Entity 93434	GrantOption · Derivative	30,000	$0.00 Strike: $7.71	$0.00	Disclosure SEC source: 0001493152-16-014583 · form4.xml · derivative · entry 1 SIDRANSKY DAVID · CIK 0001277161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2026-11-03 F1 · shares: This award relates to an annual grant awarded by the Compensation Committee following the completion of our 2016 Fiscal Year and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on November 3, 2017, one-third on November 3, 2018, and will be fully vested on November 3, 2019. Read SEC document
November 01, 2016 Filed Nov 3, 2016 18:31 UTC	CHAMPIONS ONCOLOGY, INC. CSBR · Entity 7013	GrantStock Options · Derivative	16,667	$0.00 Strike: $1.59	$0.00	Disclosure SEC source: 0001144204-16-131342 · v452159_4.xml · derivative · entry 1 SIDRANSKY DAVID · CIK 0001277161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires 2021-10-31 F1 · derivative.exercise_date: The options vest and are exercisable over a twelve month period, with vesting to occur on November 1, 2016, February 1, 2017, May 1, 2017 and August 1, 2017, respectively. Read SEC document
July 16, 2013 Filed Oct 26, 2018 01:37 UTC	Orgenesis Inc. ORGS · Entity 81814	GrantStock Option · Derivative	20,834	$0.00 Strike: $9.00	$0.00	Disclosure SEC source: 0001062993-18-004211 · form4.xml · derivative · entry 1 SIDRANSKY DAVID · CIK 0001277161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,834 Underlying: Common Stock · 20,834 shares Expires 2023-07-16 F1 · shares: Represents post-reverse stock split share amounts. F2 · derivative.exercise_date: These options were awarded under the Issuer's 2012 Equity Incentive Plan to purchase shares of common stock of the Issuer and vested over a period of 5 years, with 20% of the award vesting at the end of each successive anniversary of the award date. F1 · derivative.underlying_shares: Represents post-reverse stock split share amounts. F1 · balance_after: Represents post-reverse stock split share amounts. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.